BIO:NYE-Bio-Rad Laboratories Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 753.58

Change

0.00 (0.00)%

Market Cap

USD 22.32B

Volume

0.11M

Avg Analyst Target

USD 930.00 (+23.41%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Address: 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

N/A

USD224.65B 31.44 21.09
MDT Medtronic plc

N/A

USD165.66B 43.05 24.20
SYK Stryker Corporation

N/A

USD104.24B 50.53 28.85
EW Edwards Lifesciences Corporati..

N/A

USD72.67B 50.60 53.08
BSX Boston Scientific Corporation

N/A

USD63.85B 121.52 33.76
PHG Koninklijke Philips N.V

N/A

USD43.76B 10.00 36.47
ZBH Zimmer Biomet Holdings Inc

N/A

USD31.41B 34.26 17.64
STE STERIS plc

N/A

USD23.47B 71.78 37.84
BIO-B Bio-Rad Laboratories Inc

N/A

USD22.32B 5.44 3.86
SNN Smith & Nephew plc

N/A

USD15.68B 28.31 14.76

ETFs Containing BIO

Symbol Name Weight Mer Price(Change) Market Cap
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

N/A

USD0.02B
FXH First Trust Health Care A.. 0.00 % 0.61 %

N/A

USD1.52B
SPGP Invesco S&P 500 GARP ETF 0.00 % 0.34 %

N/A

USD0.55B
DRDR:LSE iShares IV Public Limited.. 0.00 % 0.40 %

N/A

USD2.38B
HEAL:LSE iShares IV Public Limited.. 0.00 % 0.40 %

N/A

USD2.38B
NSGE:CA NBI Sustainable Global Eq.. 0.00 % 0.74 %

N/A

USD0.31B
GERM ETF Managers Trust - ETFM.. 0.00 % 0.68 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.79 %

N/A

N/A
PFUT Putnam Sustainable Future.. 0.00 % 0.64 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.27% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.27% 84% B 75% C
Trailing 12 Months  
Capital Gain 29.55% 76% C 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.55% 76% C 52% F
Trailing 5 Years  
Capital Gain 362.63% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 362.63% 94% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 34.61% 84% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.61% 84% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 21.05% 64% D 55% F
Risk Adjusted Return 164.44% 88% B+ 99% A+
Market Capitalization 22.32B 71% C- 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.62 95% A 89% B+
Price/Book Ratio 1.85 89% B+ 52% F
Price / Cash Flow Ratio 38.79 29% F 10% F
EV/EBITDA 3.86 91% A- 88% B+
Management Effectiveness  
Return on Equity 42.70% 96% A 93% A
Return on Invested Capital 18.80% 97% A+ 90% A-
Return on Assets 2.85% 43% F 53% F
Debt to Equity Ratio 0.12% 100% A+ 94% A
Technical Ratios  
Short Ratio 3.10 63% D 37% F
Short Percent 2.22% 54% F 61% D-
Beta 0.89 63% D 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector